Affymax Home
Investors
Annual Report
Press Releases
Stock Information
SEC Filings
Corporate Governance
Analyst Coverage
Events and Webcasts
FAQs
Email Alerts
Information Requests

Corporate Profile

Affymax, Inc. is a biopharmaceutical company developing novel peptide-based drug candidates to improve the treatment of serious and often life-threatening conditions. Affymax's product candidate, Hematide™ is currently in Phase 3 clinical trials for the treatment of anemia associated with chronic renal failure and is in Phase 2 clinical trials for the treatment of anemia in cancer patients.

Webcasts

May 21, 2008
2008 Citi Investment Research Global Health Care Conference

Recent Press Releases

Jul 9, 2008
Affymax Completes Enrollment in PEARL 1, the First of Four Phase 3 Clinical Trials of Hematide(TM) to Treat Anemia in Chronic Renal Failure Patients

Jun 30, 2008
Affymax Initiates Clinical Trial of Hematide(TM) to Evaluate Correction of Anemia in Chronic Renal Failure Patients on Dialysis


(650) 812-8700
investors@affymax.com

Transfer Agent:
Computershare Trust Company, Inc.
350 Indiana Street, Suite 800, Golden, Colorado, 80401


(650) 812-8700
media@affymax.com

Briefcase  Briefcase
Download Center  Download Library
Email Alerts  Email Alerts
Glossary  Glossary
RSS  RSS News Feeds